Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer, Teva Accused of Violating Antitrust Law

By Pharmaceutical Processing | December 2, 2011

In a complaint filed in a U.S. court, Pfizer and Teva have been accused by five prescription drug retailers of violating antitrust law by conspiring to delay the launch of a generic version of Effexor XR (venlafaxine). Teva launched a generic version of the antidepressant in July last year under the terms of a 2006 settlement agreement with Pfizer.

 

The retailers, which include Walgreen and Kroger, claim that Pfizer’s Wyeth unit “engaged in an overarching anticompetitive scheme to prevent and delay the approval and marketing of generic versions of Effexor XR.” According to the suit filed in district court in Trenton, New Jersey, Wyeth did this by obtaining fraudulent patents, engaging in “sham litigation,” and entering a price-fixing agreement with Teva. “As a result of defendants’ exclusionary conduct, generic versions of Effexor XR were illegally blocked from the marketplace from June 2008 through at least June 2010,” the complaint noted.

 

Pfizer spokesman Christopher Loder said the company “categorically denies the claims,” adding that “Wyeth obtained its patents protecting Effexor XR lawfully, and the company intends to defend itself vigorously against these claims.” Teva spokeswoman Denise Bradley remarked that the drugmaker believes the lawsuit has no merit.

 

Global sales of Effexor XR in the nine months ended September 30 reached $537 million, down 64 percent from a year earlier, mainly reflecting increased generic competition.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE